Insider transactions

SCOPIA CAPITAL MANAGEMENT LP

CIK 1279150 · last filed 2019-05-30

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$627.00M
Companies
4
Total Filings
27
Lifetime Open-Market Net
$119.04M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

ITRI price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
152 WEST 57TH STREET
33RD FLOOR
NEW YORK, NY 10019
Phone
(212) 370-0303
State of Incorporation
DE
Formerly Known As
SCOPIA CAPITAL MANAGEMENT LLC (2013–2014)
SCOPIA FUND MANAGEMENT, LLC (2012–2013)
SCOPIA MANAGEMENT INC (2004–2012)
Related Filers
Jeremy Mindich — 109 joint filings, latest 2019-05-30
Matthew Sirovich — 109 joint filings, latest 2019-05-30
Scopia Management, Inc. — 85 joint filings, latest 2019-05-30
BRINKS CO — 3 joint filings, latest 2017-02-14
MYRIAD GENETICS INC — 3 joint filings, latest 2017-02-14
Emergent BioSolutions Inc. — 2 joint filings, latest 2013-02-14
LA JOLLA PHARMACEUTICAL CO — 2 joint filings, latest 2019-04-10
Lantheus Holdings, Inc. — 2 joint filings, latest 2017-02-14
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ITRI 10%+ Owner 3,926,804 $87.65 $344.18M $164.32M 11 2019-05-30
Acorda Therapeutics, Inc. (ACOR) Delisted 10%+ Owner 39,643 $0.66 $26.2K -$49.11M 9 2019-01-28
Barzel Industries Inc. (TONSW) Delisted 10%+ Owner 2,634,673 — — $0 1 2008-08-13
CENT 10%+ Owner 6,232,134 $45.38 $282.81M $3.83M 6 2008-05-23

Recent Filings · Page 3 of 3

27 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2008-08-13 Barzel Industries Inc. (TONSW) Delisted Other (J) +1,532,775 $0 EDGAR
2008-05-23 CENT Mixed −450,000 -$3.14M EDGAR
2008-05-13 CENT Buy (P) +90,741 $481.4K EDGAR
2008-05-07 CENT Buy (P) +2,964 $14.7K EDGAR
2008-05-05 CENT Buy (P) +569,040 $2.84M EDGAR
2008-04-24 CENT Buy (P) +330,444 $1.39M EDGAR
2008-04-03 CENT Buy (P) +506,655 $2.24M EDGAR
Showing 21–27 of 27
Page 3 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.